Medical Forum / Diseases and Disorders / Lupus / April 2006
ABOUT SLE STUDY...
|
|
Thread rating:  |
julia - 28 Apr 2006 23:40 GMT DERMATOVENEROLOGY. ABOUT SLE STUDY. AUTHOR A LECTURE M.D.REBROV FROM SARATOV PUBLIC MEDICINAL UNIVERSITY.
SLE-IS a disease,developming on basis of geneticaly due imperfection a immunoregulatory processes,leading to a forming immunocomlex inflammatory,consequence of which and being the defeate of many organs and systems. Frequency a sle 4-250 cases for 100 000 population/year.In usa annual prevalence a sle is =50-70 a new cases for 1 million population. A more 70 percent with sle is age 14-40 year,peak of prevalence 14-25 y.old.COrrelation :womens and mans from 8:1 to 10:1,childrens -3:1. ETHIOLOGY. A staring role RNA-CONTAINING AND SLOW VIRUSES/RETROVIRUSES/: forming antibodies to DNA and RNA-containing viruses. presence paramixoviruse cytoplasmatic inclusions. presence tubuloreticular inclusions in epithelium and inside a lymphocytes. HAS AND MEANING:genetic factors/HLA-A1,B8,DR2,DR3/.
endocrine factors/oestrogens influence/. factors from environmen/ultraviolet rays,influence ,like bacterial and viruse infection,drugs/ SLE-IS immunocomplex disease,for which is charactered uncontrolled production the antibodies,forming immune complexs,consequensing a different signs of disease.
Circulating immune complexs laying in subendothelial layer a basal membrane of vessels a many organs.
A place of fixation a diposits /skin,kidneys,choroidal plexus,serous membranes/defining a such antigene parameter ,or antibody,like a size,charge ,molecular configuration,immunoglobulin class.
CLINICAL PICTURE.
Skin defeat-is different ,in 20-25 percent skin syndrome-a begin sign of disease,in 60-70 percent-is appearances on a different stages of disease.
Observing 28 variants a skin changes in sle from erythematosis spot to difficult bullosa rashs.
Jont problems and periarticular tissues-arthralgias in 100 percent,tendinitis,tendovaginitis,aseptic necrosis a bones-in 25 percent.
myalgias in 45-45 percent.
LUNG PROBLEMS:
in 50-80 percent dry and exudative pleuritis. vasculitis. pneumonitis. HEART AND VESSEL PROBLEMS:
dry and exudative pericarditis. myocarditis. endocarditis-mitral ,aortic,tricuspid valve. arteries a small and middle gauges. aorta and her branches. thrombosis a great vessels. trombophlebitis. gastrointestinal and liver in 50 percent cases.
gullet defeat-10-15 percent. ishemia of walls a stomach and intestine. hepatomegaly. KIDNEY DEFEAT:
LUPUS NEPHRITIS,LIKE ACTIVE FORMS:
fastprogressing , nephriti with nephrotic syndrome. nephritis with marked nephritic syndrome. nephritis with minimal urine syndrome.
CNS DEFEATE:
vasculopathy-65 percent. thrombosis and natural vasculitis-15 percent. infarctions and hemmorhagias. antibody and immunocomplex inflammatory. CLINICAL DISPLAYS:
headache. psychical dissorders. defeat of scull and peryphery nerves. seizures. visual breachs. transient breachs a cerebral circulation of the blood. LABORATORY RESEARCHS.
le-cells. antinuclear antibodies. antibodies to twospiral DNA. antibodies to onespiral DNA. anemia normocyte and normochrome,leucopenia,lymphocytopenia,thrombocytopenia.
CLASSIFICATION A SLE.
VARIANT OF COURSE:ACUTE,SUBACUTE,CHRONIC.
A DEGREE OF ACTIVITY:1-MINIMAL,2-MODERATE,3-HIGH.
ALSO INCUDING AND ARA/1982/.
julia - 29 Apr 2006 00:36 GMT CONTINUATION ABOUT A SLE STUDY. A treatment of sle. SLE-IS autoimmune disease,at the heart of pathogenesis is lies a defects of immunoregulation,leading to uncontrolling hyperproduction autoantibodies to components a own tissue and development a chronic inflammatory,affecting of many organs and systems. For sle is using: base methods of pathogenetic therapy, methods of intensive therapy, additional methods of pathogenetic therapy. supporting remedies. ABSOLUTE INDICATIONS TO TREATMENT A GLUCOCORTICOSTEROIDA IN SLE:
HIGH INFLAMMATORY ACTIVITY. DEFEAT OF INTERNAL ORGANS,IN A FIRST PLACE NEPHRITIS. HEMATOLOGIC DISSORDERS. Suppressing prednisolonum dose 1-1,5 mg/day ,on average approximately 60 mg/day,duration 4-8 weeks with gradual decreasing to supporting dose 5-10 mg/day,which is take a long time ,often for a term of life,transfer from prednisolonum dose 60 mg/day to dose 35-40 mg/day is =3 month,but to dose 15-20 mg/day -6 months.
A BASE REMEDIES FOR SLE TREATMENT.
GLUCOCOCRTOCOSTERIODS FOR INTERNAL TAKING-a most often taking prednisolonum,methylprednidolonum,taking-rarely,or like,alternative -triamcinolon. PULSE-THERAPY,LIKE GLUCOCORT.FOR INTRAVENOUSE INTRODUCTION -a most often taking methylprednisolonum. IMMUNOSUPPRESSANTS-cyclophosphamidum,imuranum,rarely taking,or,like alternative-chlorbutinum,metotrexatum,cyclosporinum A. AMINOCHINOLINE DERIVATIVE-plaquenil,rarely,like alternative-delagyl. A SCHEMES OF TREATMENT A BASE PREPARATIONS FOR SLE TREATMENT.
PREDNISOLONUM,LIKE INSIDE TAKING,FOR SUPPRESSING THERAPY 1-1,5 MG/KG/DAY/ON AVERAGE 50-60 MG/DAY/4-8 WEEKS. SUPPRTING THERAPY 5-10 MG/DAY/10-15 YEARS,OFTEN FOR A TERM OF LIFE/. METHYLPREDNISOLONUM FOR INTRAVENOUSE.
SUPPRESSING THERAPY 500-1000 MG IN COMPLIANCE WITH SCHEME A ALTERNATIVE THERAPY. SUPPORTING THERAPY-500-1000 MG 1 TIME/MONTH/TO 24 MONTHS/. CYCLOPHOSPHAMIDUM INTRAVENOUSE.
SUPPRESSING THERAPY 500 MG 1 TIME/WEEK 4 WEEKS OR 1000 MG 1-2 TIME IN COMBINATION THERAPY OR 200 MG IN1 DAY 10 TIMES/TO A TOTAL DOSE 2000 MG/MONTH/. SUPPORTING THERAPY -1000 MG 1 TIME/WEEK WITH IMTERVAL INCREASING BETWEEN INJECTIONS/TO 5 YEARS/. AZATHIOPRINUM.
SUPRESS.THERAPY-100-150 MG/DAY. SUPPORT.THERAPY-50-100 MG/DAY/TO 5 YEARS/. HYDROCHLOROQUNE.
SUPPRESS.THERAPY-600 MG/DAY. SUPPORT.THERAPY.-200-400 MG/DAY/LONG TIME,FOR A TERM OF LIFE/.
julia - 29 Apr 2006 11:49 GMT INTENSIVE THERAPY FOR SLE. A BASE INDICATION TO USE A PULSE THERAPY: active lupus-nephritis/especially with nephrotic syndrome,artherial hyperthension,fast creatinine rising/. acute difficult defeat of cns/meningoencephalitis/,encephalopolyradiculoneuritis,transversal myelitis. hematologic crisis,deep thrombocytopenia. ulcer-necrotic vasculitis. pulmonary vasculitis. high disease activity,resistance to therapy. A base method for intensive therapy a sle-pulse-therapy-taking methylprednisolonum with dose 500-1000 mg/day intravenously.
Doses is less 1000 mg methylprednisol./day is taking in a high level of side effects -in eldery patients,presence artherial hyperthension,marked heart failure.
Rarely taking dexamethasonum ,like middle dose 100-150 mg/day by a different schemes.
Appropriately taking a following schemes:
monthly introduction 100 mg methylprednisolon.duration 1 year. combination/with adding 1000 mg cyclophosphamidum/pulse-therapy,like 3 day,so and programm duration 1 year. A MOST PREVALENT METHODS THE INTENSIVE THERAPY:
classical pulse-therapy 1000 mg methylprednisolon./day intravenously droply duration 3 consistent days/3000 mg in course/ introduction intravenously a decreasing doses a methylprednisol./250-500 mg/day/to attainment a summary dose approximately 3000 mg/in course. monthly introduction introvenously 1000 mg.methylprednisol.duration 6-12 months. combination pulse-therapy intravenously 1000 mg methylprednisolonum 3 days running+1000 mg cyclophoshamidum in a 1 st and 2 nd day/methylprednis.and cyclophosphanum introductioning in series. monthly intravenouse introduction 1000 mg methylprednisolonum +100 gr cyclophosphamidum duration 12 months. monthly intravenously 1000 mg cyclophosphamidum duration 12 months. Lower dose a peroral prednisolonum is immediately after conducting a pulse-therapy a glucocorticosteroid.is a dont recommending/so as it is a possible temporary abolition syndrome/.
julia - 29 Apr 2006 22:12 GMT ADDITIONAL METHODS A PATHOGENETIC THERAPY FOR SLE. Plasmapheresis is a method of choise in acute conditions and a extremely high activity of diseases,resistance to therapy.Course for plasmapheresis is ,like 3-6 procedures every other day or 2 time/week,and programmely-1 time/month ,like monthly duration 1 year and more and to avoid syndrome "ricochet" always combining with a following intravenouse glucocort.introduction and cyclophosphamidum. Synchrone intensive therapy :conducting plasmapheresis ,like with course/3-6 procedures/ with a following combination pulse-therapy with glucocort.and cyclophosphamid. Right away after a first procedure the plasmapheresis is conducting a sequential introduction 1000 mg prednisolon.and 1000 mg cyclophosphamid.,after repeate seances in a course treatment is introduces intravenously just methylprednis.500-1000 mg. Synchrone intensive therapy also conducting a monthly duration 12 months and more. Intravenouse antibody /sandglobulin,normal person s immunoglobulin/: BLOCKADE FC-RECEPTORS AND FC-DEPEND SYNTHESIS THE AUTOANTIBODIES. ANTIIDIOPATHIC ACTIVITY. MODULATION THE ACTIVITY OF T-LYMPHOCYTES AND CYTOKINES SYNTHESIS. CHANGE A STRUCTURE AND SOLUBILITY OF CIRCULATORY IMMUNE COMPLEXS. Antibody/immunoglobulin/taking ,like intavenously-a method of choise in marked stable thrombocytopenia,in resistance to lupus nephritis therapy.Recommending preparation introduction ,like 400-500 mg/kg/day duration 3-5 sequential days,after 1 time/month fduration 6-12 months.
CYCLOSPORIN A-mechanism of effect in sle is connected with inhibition of synthesis a interferon-alfa and able a suppress of expression a ligand CD40 on a membrane of T-LYMPHOCYTES.
In sle cyclospor A .is taking a less 5 mg/kg/day,more often 2-2,5 mg/kg/day/.Indicated and effectivity in lupus nephritis/with antiproteinuric effect/,thrombocytopenia,anemia,leucopenia,skin problems in lupus,refractory to therapy a polyserositis and pleuritis.
Against a backgroung therapy with cyclosp.A,IS LOWERING A LEVEL OF ANTICARDIOLIPIN AND ANTITHROMBOCYTE ANTIBODIES.
CYCLOSPORIN A-alternative preparation a second row in intolerance and inefficency a glucocort.and cytostatic remedies.That remedy also take in pregnancy.
CELLSEPT-selective immunosuppressant .ACTIVE COMPOUND mycophenol acid-noncompetitive inhibitor a ferment,limiting a synthesis speed of guasine nucleatid,displays a cytostatic activity.
A most marked antiproliferative effect regarding a T-LYMPHOCYTES,HAS A ANTIPROLIFERATIVE EFFECT REGARDING A MESANGIAL KIDNEY CELLS,SUPPRESSES A ANTIBODIES FORMATION.
IN patients with sle-alternative a azathiprinum and cyclophosph.in a good portability.
"BIOLOGIC AGENTS"-ANTIIDIOTYPICAL MONOCLONAL ANTIBODIES,INTRAVENOUSE IMMUNOGLOBULIN,MONOCLONAL ANTIBODIES TO IMMUNOGLUBULIN-10.
AUTOLOGOUS TRANSPLANTATION A STEMM CELLS.
http://www.disser.ru -source.
translate on english from me.
|
|
|